Wire · opportunities
Tegoprazan Meets Primary Endpoint in Phase 3 NERD Trial
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 12 October 2026 · Fusion42 review
In a Phase 3 trial, Tegoprazan at doses of 50 mg and 100 mg significantly improved 24-hour heartburn-free days and nights without heartburn in patients with non-erosive reflux disease (NERD), outperforming placebo. The drug also showed superiority over lansoprazole in healing and maintaining healing in patients with erosive esophagitis, supporting its pending FDA approval.
This Wire brief sits within Fusion42's coverage of Drug Discovery.
◆ ◆ The Wire takeaway
New efficacy data on Tegoprazan boosts FDA approval prospects, making this a critical moment for drug developers in GERD treatments. You should prepare to engage with prescribing physicians and highlight P-CAB advantages over PPIs as the market opens.
◆ Coverage
1 source · 12 Oct 2026
◆ Related on Wire
◆ Topics